AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27617661
Drug: Olaparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (400 mg twice a day) in patients with BRCAm
Trial: 27617661
Drug: Olaparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (400 mg twice a day) in patients with BRCA wild-type
Trial: 21959915
Drug: Cognitive-behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural group therapy
Trial: 20151799
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus simvastatin (SMV) 1.2 mg
Trial: 18849894
Drug: Second-generation oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-generation oral antipsychotics (short-term, 5 days)
Trial: 16009795
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (atorvastatin 80 mg/d)
Trial: 16009795
Drug: Moderate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate therapy (pravastatin 40 mg/d)
Trial: 9920080
Drug: Micronized 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized 17beta‐estradiol [0.5 mg/day Estrace (E2)]
Trial: 9920080
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day elemental calcium, given as carbonate plus vitamin D (800 IU/day; Ca+D)
Trial: 9920080
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Ca+D and E2)
Trial: 2345485
Drug: Cyproheptadine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (16 mg)
Trial: 27416915
Drug: Sofosbuvir (SOF)/ledipasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF)/ledipasvir for 12 weeks in treatment experienced patients without cirrhosis
Trial: 27416915
Drug: Paritaprevir/r, ombitasvir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paritaprevir/r, ombitasvir, dasabuvir ± ribavirin for 12 weeks in treatment experienced patients without cirrhosis
Trial: 27416915
Drug: Sofosbuvir (SOF)/simeprevir/1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF)/simeprevir/1200 mg/d ribavirin for 12 weeks in re-treated cirrhotic individuals
Trial: 21272454
Drug: Interferon a‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon a‐1b combined with lamivudine (100 mg, P.O., q.d. for 6-12 months or longer)
Trial: 17605253
Drug: Artificial dermis
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial dermis and recombinant bFGF2 spray, applied twice a day after immersion bath, dressing changed every other day or every 2 days
Trial: 11483170
Drug: Cognitive task
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive task involving sequential learning, explicit processing, and working memory
Trial: 7522906
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 x 10(6) KI units intravenous bolus and 0.5 x 10(6) KI units h‐1 plus 2 x 10(6) KI units into pump prime)
Trial: 7522906
Drug: Patient group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient group (aprotinin 10(6) KI units intravenous bolus plus 10(6) KI units added to pump prime)
Trial: 25698173
Drug: Trichuris suis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichuris suis ova therapy, 2500 ova orally every second week for 12 weeks
Trial: 17922185
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (exemestane and letrozole)
Trial: 16820790
Drug: Cyclophosphamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (750 mg/m2, 13 pulses in 2 years) combined with oral prednisone (CY)
Trial: 16820790
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg/day in 2 years) combined with intravenous pulses of methylprednisolone (3 x 3 pulses of 1000 mg) and oral prednisone (AZA)
Trial: 1492307
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment modes
Trial: 2993690
Drug: SBT/CPZ (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/CPZ (0.5 g SBT + 0.5 g CPZ, 2 times/day)
Trial: 2993690
Drug: CZX (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZX (1.0 g, 2 times/day)
Trial: 31729647
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (target serum UA level ≥ 4.0 mg/dL, < 5.0 mg/dL)
Trial: 31729647
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group (serum UA level ≥ 6.0 mg/dL, < 7.0 mg/dL)
Trial: 31729647
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group
Trial: 28065445
Drug: Colchicine (1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1mg once daily for 1 month plus optimal medical treatment)
Trial: 28065445
Drug: Control (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (optimal medical treatment only)
Trial: 21493743
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (prednisolone, azathioprine, heparin‐warfarin, and dipyridamole)
Trial: 21493743
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (heparin‐warfarin and dipyridamole)
Trial: 17133785
Drug: Pioglitazone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Trial: 17133785
Drug: Rosiglitazone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Trial: 10458359
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy
Trial: 9252771
Drug: Hydrocolloid +
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid + PVP-I treatment
Trial: 9252771
Drug: Hydrocolloid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid treatment
Trial: 8389339
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat meal (30 g margarine; 1327 kJ (317 kcal))
Trial: 3040455
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (0 mg)
Trial: 3040455
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (0.1 mg)
Trial: 3040455
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (1.0 mg)
Trial: 3040455
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (10 mg)
Trial: 30003102
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment for 36 sessions
Trial: 26852398
Drug: UVB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB treatment (n=26)
Trial: 26852398
Drug: Cholecalciferol injection
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol injection (n=20)
Trial: 24931748
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment plus usual care
Trial: 19774349
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg daily)
Trial: 28959158
Drug: Pre-workout supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-workout supplement (PWS) - Reckless™
Trial: 23089176
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pregabalin, cetirizine, and pheniramine maleate
Trial: 23089176
Drug: Antihistaminic combination
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistaminic combination (cetirizine with pheniramine maleate)
Trial: 21647425
Drug: Polypill (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg)
Trial: 19665601
Drug: lasofoxifene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lasofoxifene (0.25 mg/d)
Trial: 9140673
Drug: Bunazosin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin (6 and 12 mg once daily for 12 weeks)
Trial: 9140673
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 and 100 mg once daily for 12 weeks)
Trial: 29423403
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + clavulanic acid (1 gr. tablet given 12 hours and 1 hour before surgery)
Trial: 26699529
Drug: Cefepime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Trial: 26699529
Drug: Ceftriaxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Trial: 21214368
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) (685 nm, energy density 10 J/cm(2)) in addition to conventional therapy
Trial: 15620772
Drug: Chesterfield stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chesterfield stent for palatal endosseous implant placement
Trial: 9797758
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled beclomethasone dipropionate (BDP) 500 micrograms three times daily for two months
Trial: 9797758
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled beclomethasone dipropionate (BDP)
Trial: 7544851
Drug: Consolidation Arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Arm A: cytosine arabinoside 200 mg/m2 daily for 7 days and daunorubicin 45 mg/m2 daily for 3 days for three courses
Trial: 7544851
Drug: Consolidation Arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Arm B: one course as in Arm A followed by amsacrine 120 mg/m2 daily for 5 days and a 5-day continuous infusion of azacytidine 150 mg/m2/day
Trial: 7544851
Drug: Consolidation Arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Arm C: thioguanine and cytosine arabinoside 100 mg/m2 every 12 h and daunorubicin 10 mg/m2 daily for 5 days for three courses followed by four maintenance courses of cytosine arabinoside 100 mg/m2 daily for 5 days and daunorubicin 45 mg/m2 for 2 days every 13 weeks
Trial: 7544851
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy with the same or different drugs used in induction
Trial: 8448264
Drug: Insulin response
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin response
Trial: 22845185
Drug: Subcutaneous Triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Triptorelin acetate (0.1 mg/m(2), to a maximum of 0.1 mg)
Trial: 22845185
Drug: Intravenous GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous GnRH 100 μg
Trial: 18443672
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) tramadol 200 mg, titrated to a maximum of 400 mg per day
Trial: 18443672
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) diclofenac 75 mg, titrated to a maximum of 100 mg once daily or 75 mg twice a day
Trial: 1571904
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HFX) with total doses of 6720, 7200, 7680, and 8160 cGy, using 120 cGy twice daily, 5 days per week.
Trial: 1571904
Drug: Delays of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delays of 5 days or more in treatment.
Trial: 6463064
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cephradine
Trial: 6463064
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg flucloxacillin plus 500 mg ampicillin
Trial: 29582946
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cannabis (6 patients)
Trial: 29582946
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cannabis (8 patients)
Trial: 25016757
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB therapy for 12 weeks
Trial: 15831780
Drug: Cefpodoxime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime (400 mg)
Trial: 9017772
Drug: Cefixime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (400 mg)
Trial: 11572104
Drug: New cognitive-emotional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cognitive-emotional cognitive-behavioral therapy programmes (experimental group)
Trial: 7703703
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and Behavioral Marital Therapy (ABMT)
Trial: 7703703
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment dropouts
Trial: 3477353
Drug: Special caries
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special caries preventive program with controlled antimicrobial treatment using Streptococcus mutans as an indicator organism.
Trial: 31898212
Drug: Combination anti-depressants
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination anti-depressants
Trial: 31898212
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antipsychotics and anti-depressants
Trial: 19061746
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (8 weekly sessions in the first 2 months, followed by biweekly sessions for 4 months)
Trial: 16547994
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid intake
Trial: 7503000
Drug: Integrelin (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrelin (dosing regimens: 180 and 135 micrograms/kg bolus, followed by 0.75 micrograms/kg/min infusion)
Trial: 7503000
Drug: Integrelin (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrelin (0.50 micrograms/kg/min infusion)
Trial: 7503000
Drug: Integrelin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrelin with aspirin and heparin
Trial: 28288570
Drug: Tolvaptan 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15, 30 and 45 mg
Trial: 21086279
Drug: Chlorhexidine/benzydamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine/benzydamine plus paracetamol
Trial: 21086279
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus paracetamol
Trial: 14604457
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy in patients who developed depression within the first 4 weeks
Trial: 14604457
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy in patients who developed depression later
Trial: 14604457
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy in patients with no psychiatric symptoms
Trial: 9038464
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia using morphine 1 mg bolus with a 10-min lockout and no background infusion
Trial: 9038464
Drug: Intramuscular codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular codeine phosphate
Trial: 6342841
Drug: Propranolol, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 160 mg/day
Trial: 3993546
Drug: Atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 100 mg/day
Trial: 31983653
Drug: CNIC polypill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNIC polypill (atorvastatin 40mg/ramipril 10mg/aspirin 100mg)
Trial: 31983653
Drug: Atorvastatin (40mg)
RxNorm normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40mg)
Trial: 28033332
Drug: Direct Renin
RxNorm normalized name: DIRECT RENIN INHIBITOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Renin Inhibitor (DRI) - Aliskiren
Trial: 25006068
Drug: Zilpaterol hydrochloride
RxNorm normalized name: zilpaterol hydrochloride
DrugBank: Zilpaterol (DB11479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilpaterol hydrochloride (ZH; 8.3 mg/kg [100% DM basis]) for 20 d
Trial: 25006068
Drug: Ractopamine hydrochloride
RxNorm normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ractopamine hydrochloride (RH; 30.1 mg/kg [100% DM basis]) for 28 d
Trial: 25006068
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet containing no β‐agonists
Trial: 22865016
Drug: Combined behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined behavioral management and medication management intervention
Trial: 12208438
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg) + Thiopental (3 mg/kg)
Trial: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.3 mg/kg per day with oral leucovorin (LV) at a dose of 100 mg every hour for four doses before FUdR infusion and then every 4 hours during FUdR treatment.
Trial: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.25 mg/kg per day with oral leucovorin (LV).
Trial: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.375 mg/kg per day with oral leucovorin (LV).
Trial: 7469003
Drug: Atosil (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosil (as a histamine blocker)
Trial: 29242062
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) at a dosage of 5 × 10^6 MSCs per injection, 30 injections total.
Trial: 29242062
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (control group).
Trial: 20395820
Drug: Intrathecal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ketorolac (0.5-2.0 mg)
Trial: 20395820
Drug: Intrathecal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ketorolac (2.0 mg)
Trial: 10759273
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone followed by misoprostol 400 µg
Trial: 10759273
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone followed by misoprostol 400 µg
Trial: 3103546
Drug: Fat emulsion
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat emulsion administered at a constant rate over 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg